We have asked some experts in the space what they really think and know. We share their insight on everything from the world of companion diagnostics.

Diaceutics publishes a number of articles on a variety of topics relevant to the personalized medicine and molecular diagnostics space in a broad number of publications.

Our Diaceutics PM Buzz provides you with a monthly snapshot of news, events and top personalized medicine headlines, culled from hundreds of sources by our expert team.

 
How ready are you personally for personalized medicine?

Personalized medicine is rapidly becoming the predominant business model for Pharmaceutical companies. 2900 executives to date ( 104 per week) have ranked their own and teams readiness for personalized medicine against their peers in the industry using our 5 minute checkbox index.

  • CASE STUDY

    HERCEPTIN

    Genentech

    How multiple areas of patient “leakage” in the diagnostic program led to the loss of patients and several billion dollars in prescriptions.

  • CASE STUDY

    Epzicom

    GlaxoSmithKline

    The positive impact of taking a proactive approach to a targeted safety strategy.

  • CASE STUDY

    Selzentry

    Pfizer

    A loose partnering strategy and exclusive diagnostic relationship causes a negative impact on therapy sales.

  • CASE STUDY

    Tysabri

    Elan/Biogen Idec

    Post approval identification of the need for a diagnostic, handled correctly, can actually improve a drugs commercial success.

  • CASE STUDY

    Xalkori

    Pfizer

    Smart choices in test technology leads to rapid adoption but test cost presents a major issue for payers and patients.